TAKEDA PHARMACEUTICAL CO LTD current report, Q4 FY2020

Abrir documento

Takeda Pharmaceutical Co Ltd: 144th Interim Business Report Summary

Business Context and Reporting Period

This Form 6-K filing presents the 144th Interim Business Report for Takeda Pharmaceutical Company Limited for the six-month period ended September 30, 2020. The report covers consolidated financial results, operational performance across core therapeutic areas, and an updated outlook for the fiscal year ending March 31, 2021 (FY2020).

Key Financial Metrics

Metric (Billion JPY) FY2019 H1 FY2020 H1 Change
Revenue 1,660.2 1,590.8 (4.2)%
Operating Profit 109.0 215.6 +97.7%
Net Profit for the Period 74.8 86.6 +15.7%
Cost of Sales (562.0) (487.7) (13.2)%
R&D Expenses (230.4) (225.0) (2.3)%
Cash and Cash Equivalents 637.6 (Mar 2020) 630.9 (Sep 2020) N/A
Total Debt (Bonds & Loans) 5,093.3 (Mar 2020) 4,908.0 (Sep 2020) N/A

Underlying Results: Underlying Revenue Growth was +0.5%. Underlying Core Operating Profit Growth was +1.9%, with a margin of 31.6%. Underlying Core EPS Growth was -0.4%.

Material Changes vs. Prior Period

  • Revenue Decline: Total revenue decreased 4.2% primarily due to a 2.7 percentage point negative impact from yen appreciation and divestitures completed in the prior fiscal year. Off-patented products (e.g., ULORIC, COLCRYS) also contributed to the decline.
  • Operating Profit Surge: Operating profit nearly doubled (+97.7%) driven by a one-time gain of 60.2 billion JPY from the release of the obligation to divest the SHP647 pipeline compound. Excluding this, core operations benefited from cost synergies and lower SG&A expenses due to reduced travel and events during the pandemic.
  • Therapeutic Area Performance:
    • Gastroenterology (GI): Revenue increased 11.2%, led by strong growth in ENTYVIO (+22.9%) and TAKECAB (+14.2%).
    • Rare Diseases: Revenue decreased 9.9% due to declines in Rare Hematology (ADVATE, FEIBA) and Rare Metabolic (NATPARA recall impact). Hereditary Angioedema grew 20.9% driven by TAKHZYRO.
    • Oncology: Revenue decreased 2.2%. Growth in NINLARO and ADCETRIS was offset by a 21.4% decline in VELCADE due to generic competition and COVID-19 related patient visit reductions.
    • Neuroscience: Revenue decreased 2.8%, impacted by generic erosion of REMINYL and loss of exclusivity for ROZEREM and ADDERALL XR.
  • COVID-19 Impact: The pandemic had no material effect on overall revenue. While Neuroscience saw early disruptions due to reduced patient visits, products with convenient administration profiles (e.g., NINLARO) saw expansion. These trends normalized by the end of the period.

Guidance, Outlook, and Risks

Revised FY2020 Forecast (Full Year):

  • Revenue: Revised down to 3,200.0 billion JPY (from 3,250.0 billion) due to unfavorable foreign exchange assumptions.
  • Operating Profit: Revised up to 434.0 billion JPY (from 395.0 billion), reflecting expected one-time gains from announced divestitures.
  • Net Profit: Revised up to 124.0 billion JPY (from 92.0 billion).
  • Core Operating Profit: Unchanged at 984.0 billion JPY.

Management Guidance: Remains unchanged with expectations for low-single-digit Underlying Revenue Growth, high-single-digit Underlying Core Operating Profit Growth, and low-teen Underlying Core EPS Growth.

Risks and Contingencies:

  • COVID-19: Potential for future disruptions to supply chains, clinical trials, and demand if lockdowns extend or new outbreaks occur.
  • Divestitures: The sale of Takeda Consumer Healthcare Company Limited (TCHC) to Blackstone is expected to close by March 31, 2021, with an anticipated pre-tax gain of ~140 billion JPY, though this is not included in the current revised forecast.
  • Competition: Continued pressure from generic entries and competitor launches (e.g., subcutaneous VELCADE).

Key Facts for Investor Verification

  • One-Time Gains: Verify the sustainability of the 97.7% operating profit increase, which was heavily influenced by a 60.2 billion JPY non-recurring gain related to the SHP647 divestiture obligation release.
  • FX Sensitivity: Monitor the impact of yen appreciation, which negatively impacted reported revenue by 2.7 percentage points and led to a downward revision in full-year revenue guidance.
  • Divestiture Timeline: Track the closing of the TCHC sale to Blackstone, as the anticipated 140 billion JPY gain is excluded from the current forecast but could significantly impact year-end results.
  • Product Mix Shifts: Assess the long-term trajectory of Rare Hematology products (ADVATE, FEIBA) facing competitive pressure versus the growth of newer assets like TAKHZYRO and ENTYVIO.
  • Underlying vs. Reported: Note the divergence between reported revenue decline (-4.2%) and underlying revenue growth (+0.5%), highlighting the impact of divestitures and currency fluctuations.